NIMGenetics is a leading genetic diagnostic laboratory services business based in Spain.  The company currently serves over 500 medical centres and c.1500 clinicians.


Genetic testing is one of the fastest growing markets in healthcare as it offers considerable medical applications such as early and precise diagnosis, better understanding of the predisposition for diseases and better understanding of individuals’ reaction to a drug. Genetic testing is now becoming widely available and has tremendous potential in improving patient outcomes and reducing healthcare cost.

Investment Rationale

NIMGenetics represents an ideal platform to enter the extremely attractive clinical genetics and pharmacogenomics markets. Apposite’s investment will enable NIM Genetics to further develop its service offering in other medical areas, as well as support its international expansion especially in Latin America.